Malaysian Healthcare May Benefit from Medical Tourism, Biopharma Push -- Market Talk

Dow Jones

Feb 19

0158 GMT - The Malaysian healthcare sector may benefit from high-acuity medical tourism and more self-sufficient biopharmaceutical manufacturing and distribution this year, MBSB Research says in a note. The outlook is supported by an aging population, rising demand for precision treatments and government incentives for both public and private healthcare providers, it says. Ongoing digitalization and adoption of artificial intelligence in hospital administration and medical equipment should also enhance efficiency, it says. However, downside risks remain, including increases in medical costs, potential shifts in drug policies and pricing pressures stemming from global trade tariffs, it adds. MBSB maintains a positive rating on the Malaysian healthcare sector.(yingxian.wong@wsj.com)

(END) Dow Jones Newswires

February 18, 2026 20:58 ET (01:58 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2612475661"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612475661\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612475661?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-19 09:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612475661","market":"nz","top_or_hot":-1,"title":"Malaysian Healthcare May Benefit from Medical Tourism, Biopharma Push -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0158 GMT - The Malaysian healthcare sector may benefit from high-acuity medical tourism and more self-sufficient biopharmaceutical manufacturing and distribution this year, MBSB Research says in a note. The outlook is supported by an aging population, rising demand for precision treatments and government incentives for both public and private healthcare providers, it says. Ongoing digitalization and adoption of artificial intelligence in hospital administration and medical equipment should also enhance efficiency, it says. However, downside risks remain, including increases in medical costs, potential shifts in drug policies and pricing pressures stemming from global trade tariffs, it adds. MBSB maintains a positive rating on the Malaysian healthcare sector.(yingxian.wong@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 18, 2026 20:58 ET (01:58 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Malaysian Healthcare May Benefit from Medical Tourism, Biopharma Push -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMalaysian Healthcare May Benefit from Medical Tourism, Biopharma Push -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-19 09:58</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0158 GMT - The Malaysian healthcare sector may benefit from high-acuity medical tourism and more self-sufficient biopharmaceutical manufacturing and distribution this year, MBSB Research says in a note. The outlook is supported by an aging population, rising demand for precision treatments and government incentives for both public and private healthcare providers, it says. Ongoing digitalization and adoption of artificial intelligence in hospital administration and medical equipment should also enhance efficiency, it says. However, downside risks remain, including increases in medical costs, potential shifts in drug policies and pricing pressures stemming from global trade tariffs, it adds. MBSB maintains a positive rating on the Malaysian healthcare sector.(yingxian.wong@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 18, 2026 20:58 ET (01:58 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4137","symbol_name":"综合支持服务","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2612475661","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612475661","pubTimestamp":1771466280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0158 GMT - The Malaysian healthcare sector may benefit from high-acuity medical tourism and more self-sufficient biopharmaceutical manufacturing and distribution this year, MBSB Research says in a note. The outlook is supported by an aging population, rising demand for precision treatments and government incentives for both public and private healthcare providers, it says. Ongoing digitalization and adoption of artificial intelligence in hospital administration and medical equipment should also enhance efficiency, it says. However, downside risks remain, including increases in medical costs, potential shifts in drug policies and pricing pressures stemming from global trade tariffs, it adds. MBSB maintains a positive rating on the Malaysian healthcare sector.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4137":"综合支持服务","BK4585":"ETF&股票定投概念","BK4581":"高盛持仓","LABU":"三倍做多标普生物-Direxion","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","XBI":"SPDR S&P Biotech ETF","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","HCSG":"Healthcare Svcs Group Inc","BK4588":"碎股","XLV":"健康照护类股ETF-SPDR"},"translate_title":"马来西亚医疗保健可能受益于医疗旅游和生物制药的推动——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XBI":0.6,"LABU":0.6,"HCSG":1.5,"XLV":1.5},"content_text":"0158 GMT - The Malaysian healthcare sector may benefit from high-acuity medical tourism and more self-sufficient biopharmaceutical manufacturing and distribution this year, MBSB Research says in a note. The outlook is supported by an aging population, rising demand for precision treatments and government incentives for both public and private healthcare providers, it says. Ongoing digitalization and adoption of artificial intelligence in hospital administration and medical equipment should also enhance efficiency, it says. However, downside risks remain, including increases in medical costs, potential shifts in drug policies and pricing pressures stemming from global trade tariffs, it adds. MBSB maintains a positive rating on the Malaysian healthcare sector.(yingxian.wong@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 18, 2026 20:58 ET (01:58 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}